Request Trial
voodoo13-shutterstock-com
VooDoo13 / Shutterstock.com
4 August 2016AmericasMark Remus

IPR: five tips for successfully challenging Orange Book patents

Inter partes review (IPR) provides an attractive alternative to district court litigation. The Patent Trial and Appeal Board (PTAB) applies a lower burden of proof and reaches a decision more quickly and cheaply than district courts. Generic pharmaceutical companies can use these advantages to get their products to market faster and more cost-effectively. The following are five tips for a successful IPR challenge.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Hikma triumphs at SCOTUS in landmark skinny-label ruling
4 June 2026   Justices refuse to place generic drug makers “between a rock and a hard place,” in a landmark ruling clarifying induced patent infringement in pharma.
Americas
Heated LNP litigation puts Moderna and Acuitas in the spotlight
3 June 2026   A district court has thrown out one challenge over the vaccine delivery technology, while a separate appeal could affect protections available to government contractors during national emergencies.
Americas
J&J unit's valuable heart pump saved by 'rare' patent defence
1 June 2026   A district jury has handed a J&J unit a clean sweep in its defence against a rival's heart pump patent claims, delivering a win under the seldom-invoked reverse doctrine of equivalents.


Editor's picks

Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026

Editor's picks

Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026
Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026
Americas
Penile implant maker’s $17m trade secret award unravels
20 April 2026
Biotechnology
Closing the women's health gap offers ‘benefits for all’
7 April 2026
Europe
European patent offices raise fees
2 April 2026
Americas
Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market
1 April 2026

More features

Hikma triumphs at SCOTUS in landmark skinny-label ruling
Pfizer strikes $10.5 billion oncology deal with Chinese biotech
Dehns appoints head of litigation following wave of senior hires
Chadha & Chadha hires former Remfry & Sagar patent partner
Heated LNP litigation puts Moderna and Acuitas in the spotlight
UPC dispute resolution forum opens with ceremony in Slovenia
J&J unit's valuable heart pump saved by 'rare' patent defence
Federal Circuit tosses $59m trade secrets judgment against EOFlow